1月9日沪指上涨0.92%，市场两融余额为26276.01亿元，较前一交易日增加69.91亿元。 证券时报·数据宝统计显示，截至1月9日，沪市两融余额13212.13亿元，较前一交易日增加34.55亿元； 深市两融余额12979.40亿元，较前一交易日增加34.76亿元；北交所两融余额84.48亿元，较前一交易日 增加0.61亿元；深沪北两融余额合计26276.01亿元，较前一交易日增加69.91亿元。 融资余额降幅前20只个股 | 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 | 当日涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | | 920564 | 天润科 技 | 965.15 | -56.71 | -5.25 | 计算机 | | 920641 | 格利尔 | 573.04 | -34.23 | 29.99 | 家用电器 | | 920158 | 长江能 科 | 443.10 | -31.56 | -0.12 | 机械设备 | | 603172 | 万丰股 份 | 3088.14 | - ...

Core Viewpoint - The article discusses the development and commercialization of brain-computer interface (BCI) technology, highlighting its market potential, competitive landscape, and various applications, particularly in the medical field [3][5]. Group 1: Brain-Computer Interface Overview - BCI technology establishes a direct communication pathway between the brain and external devices, with steady progress in commercialization leading to vast market opportunities [3]. - The competitive landscape in China's BCI sector is still in its early stages, with most companies being small and not yet in a saturated market [3]. - There are two main types of BCI products: invasive BCIs, which offer significant signal quality advantages, and non-invasive BCIs, which are safer and easier to operate, serving as a complement to invasive types [3]. - Current applications are primarily in the medical field, with future potential to expand into non-medical areas [3]. - The industry chain has high technological barriers at the upstream level, while the mid and downstream sectors exhibit strong agglomeration effects [3]. Group 2: Global Leader Neuralink's Path to Industrialization - Neuralink, a global pioneer in BCI, is expected to enter the industrial application phase by 2025, with 12 patients having successfully implanted devices [4]. - The company plans to scale production of BCI devices starting in 2026, transitioning from laboratory research to large-scale manufacturing [4]. - Neuralink has outlined a three-step technology iteration plan, aiming to increase the number of electrodes in implants significantly by 2028 to enable comprehensive brain connectivity [4]. - The company has identified three core product lines: Telepathy for motor function recovery, Blindsight for visual perception restoration, and Deep for neurological function recovery [4]. - Neuralink's competitive advantages include advanced electrode technology, precise implantation robotics, and low-power signal processing systems [4]. - The development of Neuralink offers insights for domestic companies, emphasizing the importance of interdisciplinary research, clinical collaboration, and gradual commercialization [4]. Group 3: Factors Driving BCI Industrialization in China - National strategies are guiding the BCI sector, with local policies being introduced to support its development [5]. - Clinical advancements are accelerating, with significant breakthroughs in various BCI applications, including invasive and semi-invasive systems [5][6]. - The financing market for BCI is thriving, with 24 financing events recorded in 2025, marking a 30% year-on-year increase [5]. - The supporting industry chain for BCI technology is rapidly forming, facilitating the practical application of BCI in medical, production, and daily life scenarios [6]. Group 4: Key Companies in the BCI Sector - Notable companies in the BCI field include: - Xinwei Medical (interventional BCI) - Maipu Medical (neurosurgical consumables) - Kefu Medical (bionic implant BCIs) - Meihua Medical (upstream BCI industry) - Sanbo Brain Science (neurological specialty medical group) - Weisi Medical (rehabilitation BCIs) - Mailande (rehabilitation BCIs) - Xiangyu Medical (rehabilitation BCIs) - Chengyitong (comprehensive BCIs) - Aipeng Medical (neuro-regulation BCIs) - Chuangxin Medical (exoskeleton BCIs) [11].

板块热度飙升 Wind数据显示，上周，万得脑机接口概念指数（8841700）大涨18.95%。相关概念股中，创新医疗收获 涨停五连板，南京熊猫、普利特分别录得涨停四连板，美好医疗、三博脑科等也连续4个交易日大涨。 脑机接口板块大涨的背后，是政策、技术、产业与资本的多重利好叠加释放。 2026年开年，脑机接口一跃成为全球科技与资本市场的焦点之一。 近日，特斯拉CEO马斯克宣布，旗下Neuralink公司将于2026年启动脑机接口设备的"大规模生产"，并将 转向"更加精简和几乎完全自动化的外科手术流程"，这一表态也迅速点燃了市场热情。几乎前后脚，国 内脑机接口独角兽企业强脑科技宣布完成了约20亿元融资，规模位居全球第二。 在海外量产预期、国内政策支持与临床突破的多重共振下，A股脑机接口板块掀起了涨停潮。在板块大 涨的这波行情中，提前埋伏其中的基金也明显受益，净值大幅攀升。 脑机接口，这个一度只存在于科幻作品中的概念，正加速走进现实。 政策、技术与资本共振 1月5日，华银健康生活主题灵活配置单日涨幅达11.8%，领跑全市场基金；长城消费增值混合、国泰创 新医疗混合等单日涨幅也超过10%，位居市场前十。根据2025年 ...

龙虎榜上榜 沪深交易所2026年1月9日公布的交易公开信息显示，创新医疗（002173）因日涨幅偏离值达到7%的前5 只证券，日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月9日收盘，创新医疗(002173)报收于34.64元，上涨10.0%，换手率42.68%，成交量177.67 万手，成交额60.66亿元。 当日关注点 交易信息汇总资金流向 1月9日主力资金净流入1.32亿元；游资资金净流出2.41亿元；散户资金净流入1.09亿元。 来自交易信息汇总：1月9日创新医疗主力资金净流入1.32亿元，同时因日涨幅偏离值达7%及换手 率超20%登龙虎榜。 来自龙虎榜上榜：创新医疗近5个交易日内第2次登上龙虎榜，上榜原因为日涨幅偏离值达到7%且 日换手率达到20%。 ...

Group 1 - The A-share market experienced significant fluctuations this week, with the Shanghai Composite Index rising by 3.82%, the Shenzhen Component Index by 4.40%, and the ChiNext Index by 3.89%, indicating a notable increase in trading volume [1] - The medical services, military electronics, small metals, and semiconductor sectors saw the highest gains, with brain-computer interface and commercial aerospace concept stocks performing actively [1] - The brain-computer interface sector had substantial weekly gains, with Innovative Medical rising by 61.04%, Sanbo Brain Science by 56.15%, and Meihao Medical by 56.13% [1] Group 2 - Neuralink, owned by Elon Musk, announced plans to start mass production of brain-computer interface devices in 2026, aiming to reduce the implantation cost from $1 million to between $50,000 and $100,000 [1] - The National Medical Products Administration has initiated two industry standards for brain-computer interfaces, which will support future product registration and medical insurance pricing [1] - The National Healthcare Security Administration has established guidelines for the reimbursement of invasive brain-computer interface implantation and removal fees, with Hubei and Zhejiang provinces leading the implementation, potentially lowering the financial barrier for patients [1] Group 3 - The commercial aerospace sector remained active, with Shaoyang Hydraulic rising by 84.91% and Galaxy Electronics by 60.96% [2] - The "Three-Year Action Plan for Supporting Advanced Manufacturing Transformation and Upgrading (2026-2028)" issued on January 9 includes commercial aerospace as a key focus area, aiming to accelerate breakthroughs in commercial rockets and electric vertical takeoff and landing vehicles (eVTOL) [2] - Major funds saw net inflows exceeding 1 billion yuan in companies such as Huasheng Tiancheng, Dawi Technology, and Xian Dao Intelligent, while companies like Zhongji Xuchuang and New Yisheng experienced net outflows exceeding 4 billion yuan [2]

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [14]. Core Insights - Strong Brain Technology has completed approximately 2 billion yuan in financing, making it the second-largest in the global brain-computer interface (BCI) sector, following Neuralink. This financing round was led by IDG Capital and Huaden International, with participation from industry chain companies, enabling product scaling through a "capital + manufacturing" model [4][6]. - The company focuses on non-invasive technology, with its core product, the "Super Sensor," capable of capturing brain electrical signals without the need for surgery. This technology has already assisted individuals with disabilities in performing complex movements, with plans to help one million disabled individuals regain mobility and assist ten million patients in rehabilitation over the next 5-10 years [4][6]. - Neuralink, a key player in the BCI field, is set to initiate large-scale production of BCI devices in 2026 and is advancing fully automated surgical solutions. This invasive technology complements Strong Brain Technology's non-invasive approach, collectively driving the commercialization of global BCI technology [5][6]. - The global BCI market is projected to grow rapidly, with an estimated market size of approximately 2.62 billion USD in 2024, expected to reach 2.94 billion USD in 2025, and potentially grow to 12.4 billion USD by 2034, reflecting a compound annual growth rate (CAGR) of 17.35% over the next decade. In China, the BCI market is anticipated to reach 3.2 billion yuan in 2024 and 6.14 billion yuan by 2028 [6]. Summary by Sections Financing and Market Position - Strong Brain Technology has secured around 2 billion yuan in financing, ranking second globally in the BCI sector, just behind Neuralink [4]. - The financing round was led by IDG Capital and Huaden International, with contributions from various industry chain companies [4]. Technology and Product Development - The company's non-invasive "Super Sensor" technology captures brain signals without surgery, aiding individuals with disabilities [4]. - Plans are in place to assist one million disabled individuals and ten million patients in rehabilitation over the next 5-10 years [4]. Market Growth Projections - The global BCI market is expected to grow from 2.62 billion USD in 2024 to 12.4 billion USD by 2034, with a CAGR of 17.35% [6]. - The Chinese BCI market is projected to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028 [6].

Core Insights - The article discusses the establishment of pricing for brain-computer interface (BCI) medical services in various provinces in China, highlighting the integration of these services into the healthcare system and the support from government policies [4][5][10]. Pricing and Policy Developments - The Sichuan Provincial Medical Insurance Bureau has set a maximum price for BCI services, effective from April 30, 2026, with different pricing based on hospital levels for invasive procedures [4]. - Other provinces, including Hubei, Zhejiang, and Jiangsu, have also established pricing for BCI services, with costs for invasive procedures ranging from approximately 6,000 to 6,600 yuan per procedure [5][6][7]. - The pricing structure includes insertion fees, removal fees, and adaptation fees, with some provinces incorporating non-invasive adaptation fees into insurance coverage [5][8]. Government Support and Strategic Planning - The Chinese government has outlined a strategic plan to support the BCI industry through policies that focus on planning, payment, and standards, aiming for significant advancements by 2030 [10][11]. - Multiple provinces have released action plans to promote BCI innovation and commercialization, with specific targets for clinical applications and production [11]. Technological Advancements and Market Potential - The article notes that while invasive BCI products are still in clinical trials, non-invasive products have begun to enter the market, indicating a growing application space [12]. - The industry is at a critical juncture where technological breakthroughs are expected to lead to commercial viability, supported by favorable policies and anticipated production from companies like Neuralink [15][17]. Investment Opportunities - Analysts suggest focusing on key segments of the BCI industry, including hardware suppliers, companies with core patents, and those involved in rehabilitation and industrial applications [15][16]. - Specific companies are highlighted as potential beneficiaries of the BCI market growth, including Aipeng Medical, Lepu Medical, and Xiangyu Medical, among others [16].

Core Viewpoint - The brain-computer interface (BCI) sector is expected to experience a significant wave of financing in 2026, driven by advancements in technology and supportive government policies [5][6][9]. Group 1: Market Dynamics - Non-invasive BCI company "Qiangnao Technology" recently completed a financing round of 2 billion yuan, igniting interest in BCI concept stocks [6]. - The BCI sector has seen a strong market response, with companies like Innovation Medical, Nanjing Panda, and Yanshan Technology experiencing stock price surges [7]. - Elon Musk's announcement regarding Neuralink's plans for large-scale production of BCI devices by 2026 has been a major catalyst for the current market enthusiasm [7]. Group 2: Investment Landscape - Major venture capital firms such as Sequoia China, IDG, and Baidu Ventures have invested in various BCI companies, indicating a broadening interest beyond just medical applications to technology and consumer sectors [9]. - The BCI market is transitioning from primarily medical investments to include technology and consumer-focused investments, particularly in consumer healthcare applications [9]. Group 3: Non-Invasive BCI Insights - Non-invasive BCI technology has a wide range of applications, including sleep monitoring, attention tracking, and treatment for mental health disorders, but has faced challenges due to high user education costs and product homogeneity [10][12]. - The technology has limitations in signal quality, as non-invasive methods like EEG struggle with signal clarity and resolution [10]. - Companies are shifting focus from pure brain control to developing smart prosthetics and other applications that utilize muscle signals and AI algorithms for better intent recognition [11]. Group 4: Invasive BCI Developments - Invasive BCI companies are navigating significant challenges, including safety, signal stability, and regulatory compliance, but have still managed to secure funding during market downturns [13]. - The evaluation of BCI companies has shifted from focusing solely on technical capabilities to assessing their overall operational capabilities and clinical trial progress [13]. - Notable invasive BCI companies include Borui Kang, which is pursuing a listing on the Science and Technology Innovation Board, and has reported successful clinical trials with significant patient improvements [14]. Group 5: Key Players and Innovations - Borui Kang has developed a semi-invasive BCI system that has shown promising results in clinical trials, achieving significant improvements in patient functionality [14]. - Ladder Medical focuses on ultra-flexible neural electrode technology and has successfully conducted clinical trials for spinal cord injury patients [15][16]. - Brain Tiger Technology, which aims to compete with Neuralink, utilizes silk protein for its electrodes, enhancing biocompatibility and reducing long-term damage [17]. Group 6: Future Outlook - The year 2026 is anticipated to be a pivotal moment for the BCI industry, with advancements in technology and regulatory support paving the way for broader adoption [22]. - The introduction of independent billing for BCI services by the National Healthcare Security Administration in 2025 reflects a commitment to supporting the industry's growth [22]. - Companies that establish a strong foothold in the BCI sector are likely to gain significant influence over future technologies, products, and standards [23].

Investment Rating - The report suggests a positive outlook for the invasive brain-computer interface (BCI) clinical field, indicating a broad application of the technology [5]. Core Insights - The invasive BCI technology has made significant clinical advancements, transitioning from laboratory research to practical applications, particularly in the treatment of drug-resistant epilepsy [4]. - A study conducted by a collaborative team has successfully decoded and personalized interventions for brain network activities in patients with drug-resistant epilepsy, marking a new paradigm in treatment [4]. - The research identified a specific high-frequency oscillation (fast ripple, FR) as a neural biomarker for the severity of epilepsy, allowing for targeted interventions that significantly reduce seizure frequency [4]. - Key nodes in the brain's FR network were found to be stable and safer for stimulation, with 87.5% of patients experiencing a reduction in seizure frequency by over 50% after targeted stimulation [4]. - The new approach shifts the treatment paradigm from localized resection to personalized modulation of abnormal brain networks, enhancing clinical application potential [4]. Summary by Sections Clinical Advancements - The report highlights the establishment of a specialized alliance for neuro-regulation and BCI technology in Chongqing, aimed at improving precision diagnosis and treatment for epilepsy and other neurological disorders [4]. Market Opportunities - The report recommends focusing on companies such as Innovation Medical, Aipeng Medical, and Sanbo Brain Science, which are positioned to benefit from advancements in the invasive BCI sector [5].

Market Overview - On January 9, the Shanghai Composite Index rose by 0.92%, the Shenzhen Component Index increased by 1.15%, and the ChiNext Index went up by 0.77% [1] - A total of 54 stocks appeared on the "Dragon and Tiger List" due to significant price movements, with Kunlun Wanwei (300418.SZ) seeing the highest net inflow of funds at 1.032 billion yuan [1][3] Stock Performance - Kunlun Wanwei closed up by 19.99% with a turnover rate of 16.37%, and it accounted for 10.03% of the total trading volume [1][3] - Other notable stocks included: - Lioo Co., Ltd. (利欧股份) with a 10.03% increase and a net buy of 626.66 million yuan [3] - Zhenlei Technology (臻镭科技) rose by 19% with a net buy of 550.80 million yuan [3][5] - LeiKe Defense (雷科防务) increased by 3.45% with a net buy of 527.70 million yuan [3] Institutional Activity - Institutions participated in 40 stocks on the Dragon and Tiger List, with a total net buy of 542 million yuan, buying 22 stocks and selling 18 [4] - The stock with the highest institutional net buy was Zhenlei Technology, which saw a net buy of 42.24 million yuan [5][13] Northbound Capital - Northbound funds participated in 28 stocks on the Dragon and Tiger List, with a total net buy of 1.228 billion yuan [8] - The stock with the highest net buy from northbound funds was Innovation Medical (创新医疗), with a net buy of 288 million yuan [8][11] Notable Sell-offs - The stock with the highest net sell was Xue Ren Group (雪人集团), with a net sell of 588.52 million yuan, despite a closing increase of 1.7% [4][11] - Other significant net sells included: - Jin Feng Technology (金风科技) with a net sell of 476.88 million yuan [11][14] - Hongyuan Green Energy (弘元绿能) with a net sell of 342.74 million yuan [4][14]